Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05459402 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Divided or Single Exposure (DOSE) Study

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 1, 2028 to Jun 1, 2027
    • Study completion date: Oct 1, 2028 to Jun 1, 2028
    v13
  2. Primary and study completion dates: Oct 2028 to Oct 1, 2028v12
  3. Phase: Phase 2 to Phase 2/3v11
  4. Lead sponsor: Johns Hopkins University to University of Maryland, Baltimorev10
  5. Re-verified, no change to tracked fieldsv9
Show 7 earlier versionsHide 7 earlier versions
  1. Study title shortened, about 3 wordsv8
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2023 to Feb 21, 2023
    • Site details revised
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Start date: Jan 2023 to Feb 2023v5
  5. Start date: Nov 2022 to Jan 2023v4
  6. Start date: Aug 2022 to Nov 2022
    • Primary and study completion dates: Aug 2028 to Oct 2028
    v3
  7. Study title shortened, about 7 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate whether once versus twice daily dosing of methadone will be an effective method for managing comorbid pain and opioid use disorder.
Trial Details
NCT Number NCT05459402
Lead Sponsor University of Maryland, Baltimore
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions
(from sponsor)		 Opioid Use Disorder, Chronic Pain, Methadone
Related terms Chronic Pain, Opioid-Related Disorders
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov